Longer persistence seen with Upadacitinib versus tumor necrosis factor inhibitors in rheum
Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.